Inspire Denufosol Phase II Cystic Fibrosis Data Support Early Use, Firm Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Inspire is hoping to expedite moving its cystic fibrosis therapy, INS-37217, into Phase III following better-than-expected Phase II results.
You may also be interested in...
First Cystic Fibrosis Drugs To Target Underlying Genetic Defect Are In Phase II
The first cystic fibrosis drugs to mitigate the ion transport defect underlying the disease are in Phase II, with the support of the Cystic Fibrosis Foundation’s extensive therapeutics development program.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011